Diligence memo · auto-generated · as of July 2, 2026
RheumaGen, Inc.
RheumaGen, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
RheumaGen, Inc. operates in Biotechnology, based in DENVER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
RheumaGen, Inc. has raised $7.9M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.9M on 2024-04-04.
Most recent recorded round closed around 2024-04-05.
Valuation (modeled)modeled
Provath models RheumaGen, Inc. at approximately $4.1M (range $764K–$9.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.09× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 2.2 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 7.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 52% of Biotechnology peers (4293 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.